Article

Acucela receives 'Emerging Leader' award

Acucela Inc. has been named as a recipient of the 2012 Emerging Leaders award from the Japan-U.S. Innovation Awards

Seattle-Acucela Inc. has been named as a recipient of the 2012 Emerging Leaders award from the Japan-U.S. Innovation Awards.

Acucela is a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases.

Now in its second year, the Japan-U.S. Innovation Awards program is sponsored by the Japan Society of Northern California in collaboration with the Stanford University U.S.-Asia Technology Management Center. The awards are designed to recognize the synergy between Japan and the United States by honoring outstanding companies from both countries that have achieved highly noteworthy innovation in their business or technology.

The Emerging Leaders award highlights two companies-one from Japan and one from the United States-that are young, small, dynamic, growing, entrepreneurial, and have a credible footprint in both Japan and the United States.

“It is an honor to accept this award on behalf of Acucela, and a testament to the important work our entire team contributes every day to continue the fight against blinding eye diseases,” said Ryo Kubota, MD, PhD, Acucela’s chairman, president, and chief executive officer.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.